Superoxide from NADPH oxidase upregulates type 5 phosphodiesterase in human vascular smooth muscle cells: Inhibition with iloprost and NONOate

British Journal of Pharmacology

Volumn 155, Issue 6, 2008, Pages 847-856

  Muzaffar, S ^a   Shukla, N ^a   Bond, M ^a   Sala Newby, G B ^a   Newby, A C ^a   Angelini, G D ^a   Jeremy, J Y ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

NADPH oxidase; Nitric oxide; Rho kinase; Superoxide; Type 5 PDE; Vascular smooth muscle cell

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 3,3 BIS(2 AMINOETHYL) 1 HYDROXY 2 OXOTRIAZENE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; APOCYNIN; ILOPROST; PHOSPHODIESTERASE V; RAC1 PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RHO KINASE; SUPEROXIDE; SUPEROXIDE DISMUTASE; XANTHINE; XANTHINE OXIDASE;

ARTICLE; CELL CULTURE; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

CELLS, CULTURED; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; HUMANS; ILOPROST; MUSCLE, SMOOTH, VASCULAR; NADPH OXIDASE; NITRIC OXIDE DONORS; NITROSO COMPOUNDS; SAPHENOUS VEIN; SUPEROXIDES; UP-REGULATION; VASODILATOR AGENTS;

EID: 57349121583     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.300     Document Type: Article

References (33)

1. Bond M, Sala-Newby GB, Newby AC (2004). Focal adhesion kinase (FAK)-dependent regulation of S-phase kinase-associated protein-2 (Skp-2) stability. A novel mechanism regulating smooth muscle cell proliferation. J Biol Chem 279: 37304-37310.
2. Brown JH, Del Re DP, Sussman MA (2006). The rac and rho hall of fame: a decade of hypertrophic signaling hits. Circ Res 98: 730-742.
3. Cai H, Griendling KK, Harrison DG (2003). The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 24: 471-478.
4. Cai H, Harrison DG (2000). Endothelial dysfunction in cardiovascular diseases. The role of oxidant stress. Circ Res 87: 840-844.
5. Farah S, Agazie Y, Ohan N, Ngsee JK, Liu Xj (1998). A Rho-associated protein kinase, ROKalpha, binds insulin receptor substrate-1 and modulates insulin signaling. J Biol Chem 273: 4740-4746.
6. Friebe A, Koesling D (2003). Regulation of nitric oxide sensitive guanylyl cylcase. Circ Res 93: 96-105.
7. Fung E, Fiscus RR, Yim AP, Angelini GD, Arifi AA (2005). The potential use of type-5 phosphodiesterase inhibitors in coronary artery bypass graft surgery. Chest 128: 3065-3073.
8. Goto H, Kosako H, Tanabe K, Yanagida M, Sakurai M, Amano M et al. (1998). Phosphorylation of vimentin by rho-associated kinase at a unique amino-terminal site that is specifically phosphorylated during cytokinesis. J Biol Chem 273: 11728-11736.
9. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M (2000). Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 20: 2175-2183.
10. Hordijk Pl (2006). Regulation of NADPH oxidases: the role of rac proteins. Circ Res 98: 453-462.
11. Ito M, Nakano T, Erodi F, Hawthorne DJ (2004). Myosin phosphatase: structure, regulation and function. Mol Cell Biochem 259: 197-209.
12. Izawa T, Fukata Y, Kimura T, Iwamatsu A, Dohi K, Kaibuchi K (2000). Elongation factor-1 alpha is a novel substrate of Rho-associated kinase. Biochem Biophys Res Commun 278: 72-78.
13. Jeremy JY, Jonesa RA, Kouparris A, Hotston M, Persad R, Angelini GD et al. (2007). Oxidative stress and erectile dysfunction: possible role of NADPH oxidase. Int J Impotence Res 19: 265-280.
14. Jeremy JY, Rowe D, Emsley AM, Newby AC (1999). Nitric oxide and the proliferation of vascular smooth muscle cells. Cardiovasc Res 43: 580-594.
15. Jeremy JY, Shukla N, Muzaffar S, Angelini GD (2004). Reactive oxygen species, vascular disease and cardiovascular surgery. Curr Vasc Pharmacol 2: 229-236.
16. Jin L, Ying Z, Webb RC (2004). Activation of rho/rho-kinase signalling pathway by reactive oxygen species in rat aorta. Am J Physiol 287: H1495-H1500.
17. Li JM, Shah AM (2004). Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am J Physiol Regul Integr Comp Physiol 287: R1014-R1030.
18. Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR et al. (2003). Cyclic nucleotide phosphodiesterase activity, expression and targeting of the cardiovascular system. Mol Pharmacol 64: 533-540.
19. Ming XF, Viswambharan H, Barandier C, Ruffieux J, Kaibuchi K, Rusconi S et al. (2002). Rho GTPase/Rho-kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase β/Akt in human endothelial cells. Mol Cell Biol 22: 8467-8477.
20. Muzaffar S, Jeremy JY, Angelini GD, Stuart-Smith K, Shukla N (2003). The role of the endothelium and nitric oxide synthases in modulating superoxide formation induced by endotoxin and cytokines in porcine pulmonary arteries. Thorax 58: 598-604.
21. Muzaffar S, Shukla N, Angelini GD, Jeremy JY (2004a). Nitroaspirins and SIN-1, but not aspirin, inhibit the expression of endotoxin-and cytokine- induced nadph oxidase in vascular smooth muscle cells from pig pulmonary arteries. Circulation 110: 1140-1147.
22. Muzaffar S, Shukla N, Angelini GD, Jeremy JY (2005a). Nicotinamide adenine dinucleotide phosphate oxidase: a promiscuous therapeutic target for cardiovascular drugs? Trends Cardiovasc Med 15: 278-282.
23. phox expression in porcine pulmonary endothelial cells through a cyclic GMP dependent mechanism. Br J Pharmacol 146: 109-117.
24. Muzaffar S, Shukla N, Angelini GD, Jeremy JY (2005c). Hypoxia and the expression of gp91phox and endothelial nitric oxide synthase in the pulmonary artery. Thorax 60: 305-313.
25. Muzaffar S, Shukla N, Angelini GD, Jeremy JY (2006). Superoxide auto-augments superoxide formation in isolated porcine pulmonary artery endothelial cells through upregulation of NADPH oxidase expression: inhibition with iloprost. Eur J Pharmacol 538: 108-114.
26. 2 analogue, U46619. Prostaglandins Leukot Essent Fatty Acids 78: 247-255.
27. 2α in cultured porcine pulmonary artery vascular smooth muscle cells. Br J Pharmacol 141: 488-496.
28. Peng F, Wu D, Gao B, Ingram AJ, Zhang B, Chorneyko K et al. (2008). RhoA/rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes 57: 1683-1692.
29. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA (2003). Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 93: 280-291.
30. Stolk J, Hiltermann TJ, Dijkman JH, Verhoeven AJ (1994). Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am J Respir Cell Mol Biol 11: 95-102.
31. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK (2002). Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 106: 57-62.
32. Thompson WJ, Appleman MM (1971). Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry 10: 311-316.
33. Wolfrum S, Dendorfer A, Rikitake Y, Stalker TJ, Gong Y, Scalia R et al. (2004). Inhibition of rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 24: 1842-1847.